M D Anderson Cancer Center
Houston, Texas, United States
284 recruiting
Showing 1–20 of 338 trials
Recruiting
Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Head and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8+13 more
ECOG-ACRIN Cancer Research Group189 enrolled676 locationsNCT02734537
Recruiting
Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Acute Myeloid Leukemia
Children's Oncology Group1,186 enrolled205 locationsNCT04293562
Recruiting
Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
ECOG-ACRIN Cancer Research Group288 enrolled747 locationsNCT03937635
Recruiting
Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 1Phase 2
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+5 more
PedAL BCU, LLC960 enrolled183 locationsNCT04726241
Recruiting
Phase 1Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 2
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recurrent Langerhans Cell HistiocytosisRefractory Langerhans Cell Histiocytosis
National Cancer Institute (NCI)48 enrolled117 locationsNCT05828069
Recruiting
Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recurrent B Acute Lymphoblastic LeukemiaDown Syndrome
National Cancer Institute (NCI)461 enrolled225 locationsNCT04546399
Recruiting
Phase 1Phase 2
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT04047641
Recruiting
Early Phase 1
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
Gliomas
M.D. Anderson Cancer Center40 enrolled1 locationNCT05804227
Recruiting
Phase 2
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Lung CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+10 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04789681
Recruiting
Phase 2
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Myelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid Leukemia+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT04493164
Recruiting
Early Phase 1
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center30 enrolled1 locationNCT06184321
Recruiting
Phase 2
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Prostate Cancer
M.D. Anderson Cancer Center30 enrolled1 locationNCT05873192
Recruiting
Phase 2
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
Lung Cancer
M.D. Anderson Cancer Center39 enrolled1 locationNCT05632809
Recruiting
Phase 2
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Breast CarcinomaEsophageal CarcinomaHead and Neck Carcinoma+6 more
M.D. Anderson Cancer Center5,000 enrolled1 locationNCT00991094
Recruiting
Phase 1
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Myeloma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05055063
Recruiting
Phase 1Phase 2
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Recruiting
Phase 1Phase 2
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center42 enrolled1 locationNCT05010122